Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer

Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of a humanized anti-Trop-2 IgG antibody conjugated via a hydrolysable linker to SN-38, the topoisomerase I-inhibitory active component of irinotecan. We investigated whether Trop-2-expression and homologous recombination repair (HRR)...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Cardillo, Thomas M., Rossi, Diane L., Zalath, Maria B., Liu, Donglin, Arrojo, Roberto, Sharkey, Robert M., Chang, Chien-Hsing, Goldenberg, David M.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2020
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7597411/
https://ncbi.nlm.nih.gov/pubmed/33196706
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27766
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items